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Essentials
• ERp72 is a thiol isomerase enzyme.
• ERp72 levels increase at the platelet surface during pla-
telet activation.
• We generated a humanized monoclonal antibody which
blocks ERp72 enzyme activity (anti-ERp72).
• Anti-ERp72 inhibits platelet functional responses and
thrombosis.
Summary. Background: Within the endoplasmic reticulum,
thiol isomerase enzymes modulate the formation and
rearrangement of disulfide bonds in newly folded proteins
entering the secretory pathway to ensure correct protein
folding. In addition to their intracellular importance, thiol
isomerases have been recently identified to be present on
the surface of a number of cell types where they are
important for cell function. Several thiol isomerases are
known to be present on the resting platelet surface,
including PDI, ERp5 and ERp57, and levels are increased
following platelet activation. Inhibition of the catalytic
activity of these enzymes results in diminished platelet
function and thrombosis. Aim: We previously determined
that ERp72 is present at the resting platelet surface and
levels increase upon platelet activation; however, its func-
tional role on the cell surface was unclear. We aimed to
investigate the role of ERp72 in platelet function and its
role in thrombosis. Methods: Using HuCAL technology,
fully humanized Fc-null anti-ERp72 antibodies were gen-
erated. Eleven antibodies were screened for their ability
to inhibit ERp72 activity and the most potent inhibitory
antibody (anti-ERp72) selected for further testing in pla-
telet functional assays. Results and conclusions: Anti-
ERp72 inhibited platelet aggregation, granule secretion,
calcium mobilisation and integrin activation, revealing an
important role for extracellular ERp72 in the regulation
of platelet activation. Consistent with this, infusion of
anti-ERp72 into mice protected against thrombosis.
Keywords: ERp72; platelet; platelet aggregation; redox;
thrombosis.
Introduction
Thiol isomerases are endoplasmic reticulum (ER) resident
enzymes that regulate protein folding through the reduc-
tion, isomerisation and oxidation of cysteine residues.
This enables disulfide bond modification that results in
the correction of protein folding in proteins entering the
secretory pathway. In recent years, thiol isomerases have
also been identified on the surface of cells, where levels
increase under certain pathological conditions.
ERp72, an abundant thiol isomerase, comprises 645
amino acid residues with three catalytically active thiore-
doxin-like domains similar to those found in ERp5,
ERp57 and PDI [1], and sequence analysis reveals that
ERp72 is most similar to ERp57 with 40% overall
sequence identity. The active domains of ERp72, termed
a, a’ and a°, are inter-spaced by the catalytically inactive
b-type domains that stabilize protein interactions with
substrate proteins in conjunction with the N-terminal
peptide binding c-type domain. Unlike other thiol iso-
merases which possess a C-terminal KDEL sequence for
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ER sequestration, ERp72 displays a KEEL motif at the
C-terminus [2], which is essential for ER retention
because deletion of this sequence in COS-7 cells results in
ERp72 secretion. In CHO cells, ERp72 is proposed to
function in response to cellular stress as increased protein
expression of ERp72 is observed following treatment with
either the SERCA inhibitor thapsigargin or the n-linked
glycosylation inhibitor tunicamycin, which have previ-
ously been shown to differentially cause ER stress [3].
Other roles attributed to ERp72 include: assisting the
folding of interferon-c [4] cholera toxin [5] and thyroglob-
ulin [6], either directly or through multi-isomerase
complexes. Most studies on ERp72 have focused on ER-
related functions; however, ERp72 has been detected on
the surface of neutrophils [7], where it is reported to inter-
act with and its activity to be regulated by NADPH
oxidase (NOX)-1 [8].
Multiple thiol isomerases are known to exist on the
surface of platelets, including: PDI [9], ERp5 [10],
ERp57, ERp44, ERp29 and TMX3 [11]. Using inhibitory
antibodies that are selective for PDI [12,13], ERp5 [10] or
ERp57 [14], we and other groups have demonstrated that
cell-surface inhibition of thiol isomerases results in the
inhibition of platelet aggregation, granule secretion, inte-
grin activation, integrin-mediated adhesion and thrombus
formation. The importance of these enzymes in vivo has
been studied using intravital microscopy-based techniques
in conjunction with antibody-based inhibition or in mice
lacking a specific thiol isomerase where inhibition of these
enzymes resulted in diminished thrombus formation [14–
17]. Additionally, PDI is involved in the regulation of tis-
sue factor procoagulant activity [18–20].
ERp72 is present in platelets and megakaryocytes, and
following platelet activation it is recruited to the cell sur-
face [11]. In this study, we used a fully humanized mono-
clonal anti-ERp72 antibody to determine the effects of
ERp72 inhibition on platelet function and thrombus
formation.
Methods and materials
Cross-linked collagen-related peptide (CRP-XL) was pur-
chased from Professor Richard Farndale (University of
Cambridge, Cambridge, UK) and Horm collagen (type I)
was from Takeda (Linz, Austria). Chronolume and ATP
standard reagents were from Chronolog (Havertown, PA,
USA). DIOC-6, pNPP substrate, thrombin, anti-rabbit
IgG peroxidase conjugate, reduced glutathione (GSH), oxi-
dized glutathione (GSSG), Sephadex G-25, eosin isothio-
cyanate, mammalian protease inhibitor cocktail,
glutathione agarose, bovine PDI, thioredoxin (TRX) and
fibrinogen from human plasma were purchased from
Sigma Aldrich (Poole, UK). Fura-2AM was from Thermo
Fisher Scientific (Leicester, UK). Anti-GPIb DyLight 649
conjugated platelet labelling antibody and anti-JON/A PE
conjugate were from Emfret Analytics (Bayern, Germany).
Anti-human fibrinogen FITC conjugate was from Dako
(Cambridge, UK), anti-human P-selectin PE conjugate,
anti-mouse CD62P Alexa fluor 647 conjugate (clone
RB40.34) and anti-human PAC-1 FITC conjugate were
obtained from BD biosciences (Oxford, UK). Purified
recombinant ERp72, ERp57 and ERp5 were prepared as
described previously [10,14] and outlined below. HIS-
tagged ERp46 and TMX3 constructs were purchased from
Genecopoeia (Rockville, MD, USA) and proteins prepared
using standard protocols. Humanized HuCAL Fab-
dHLX-FSx2 anti-ERp72 antibodies, control antibody and
Fab-dHLX-FSx2 FITC-conjugated secondary antibodies
were generated by AbD Serotec BioRad (Kidlington, UK).
The clone used in this study was AbD17115.
Antibody generation and screening by thiol isomerase assay
Full-length mammalian ERp72 cDNA was obtained from
Dr Mike Green (St Louis University, St Louis, MO,
USA) and subcloned into pGEX6P1 expression vector to
create an ERp72-glutathione s-transferase (ERp72-GST)
fusion protein for expression in Escherichia coli. The
fusion protein was purified by glutathione agarose affinity
chromatography, and the GST tag cleaved using PreScis-
sion protease (as described previously) [14]. Contaminants
were removed by gel filtration on a Superdex 75 purifica-
tion resin (GE Healthcare, Amersham, UK). Using puri-
fied ERp72 as an immunogen, humanized disulfide-linked
F(ab’)2 anti-ERp72 antibody fragments were generated
through the use of the Human Combinatorial Antibody
Library (HuCAL) and CysDisplay phage display system
by BioRad AbD Serotec (Kidlington, UK). High-affinity
antibodies were purified by protein G sepharose chro-
matography and affinity chromatography. To ensure
selectivity, phage displaying epitopes that cross-react with
the structurally similar thiol isomerase family members
(PDI, ERp5 and ERp57) were negatively selected against
leaving phage expressing only ERp72 selective antibodies.
Monoclonal antibodies were obtained in preservative-free
phosphate buffered saline (PBS).
Inhibition of enzyme activity was assessed using dieosin
glutathione disulfide (DI-E-GSSG) as described previ-
ously [21]. The redox activity of ERp72, ERp57, PDI,
ERp5, TMX3, ERp46 and TRX (100 nM) was assayed in
the presence of anti-ERp72 antibodies or control anti-
body (25 lg mL1) for 30 min in a fluorimeter.
Platelet preparation and stimulation
Washed human platelets from drug-free donors were pre-
pared by differential centrifugation as described previ-
ously [22] and suspended to a density of 4 9 108
cells mL1 in Tyrodes-HEPES buffer (134 mM NaCl,
2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM NaHCO3,
20 mM HEPES, 1 mM MgCl2 and 5 mM glucose, pH7.3).
Prior to stimulation, platelets were incubated with anti-
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ERp72 or control antibody for 5 min. Platelets were stim-
ulated using collagen (1 lg mL1) or thrombin
(0.1 U mL1) for 180 s in a lumi-aggregometer (Chrono-
log, Havertown, PA, USA) with continuous stirring.
Mouse blood was obtained on the day of experimentation
by cardiac puncture following termination. Platelet-rich
plasma was isolated from anticoagulated (4% w/v sodium
citrate) blood by centrifugation at 200 9 g for 8 min.
Platelets were pelleted by centrifugation at 1000 9 g for
5 min in the presence of 100 ng mL1 PGI2 and re-sus-
pended to a density of 2 9 108 cells mL1 in Tyrodes-
HEPES buffer.
SDS-PAGE and immunoblotting
Protein separation by reducing SDS-PAGE was per-
formed using 4% stacking and 10% resolving gels fol-
lowed by transfer to a polyvinylidene difluoride (PVDF)
membrane by semi-dry western blotting. Membranes were
blocked by incubation with 5% (w/v) bovine serum albu-
min (BSA) in Tris-buffered saline/Tween (TBS-T, 20 mM
Tris, 140 mM NaCl, 0.01% Tween, pH7.6). Diluted pri-
mary antibody anti-ERp72 HuCAL Fab-dHLX-FSx2
(1 lg mL1) and HuCAL Fab-dHLX-FSx2 secondary
antibody (anti-human FITC conjugate, 1 : 1000) were
added for 1 h at room temperature and blots washed in
multiple changes of TBS-T and visualized on a Typhoon
FLA 9500 scanner.
Platelet granule secretion and calcium mobilization
measurements
P-selectin exposure was measured by flow cytometry.
Washed platelets (2 9 108 cells mL1) were diluted in
HEPES-buffered saline (HBS) (3.2 mM NaCl, 0.148 mM
KCl, 0.054 mM Na2HPO4:2H2O, 0.4 mM glucose, 2 mM
HEPES, pH7.0) containing anti-human-P-selectin anti-
body (1 : 500 dilution) and either anti-ERp72 or con-
trol antibody added for 5 min prior to stimulation.
Platelets were stimulated with CRP-XL (0.5 lg mL1)
for 20 min and then fixed by dilution in paraformalde-
hyde (0.2% v/v). Mouse platelets were stained using
anti-mouse CD62P and JON/A antibodies (both at a
dilution of 1 : 500) and stimulated with thrombin
(0.1U mL1). Data for 10 000 (human platelets) or
5000 (mouse platelets) gated events were recorded using
an Accuri C6 flow cytometer (Beckton Dickinson,
Oxford, UK).
ATP secretion from dense granules was measured
using lumi-aggregometry. Washed platelets (4 9 108
cells mL1) were pre-incubated with anti-ERp72 or
control antibody for 5 min, Chronolume reagent (50 lL)
was added 2 min prior to stimulation with collagen
(1 lg mL1) and secretion recorded for 180 s.
For calcium mobilization assays, washed human plate-
lets (4 9 108 cells mL1) were loaded with FURA-2AM
calcium sensitive dye (2 lM) and then incubated with
either anti-ERp72 or control antibody for 5 min prior to
stimulation with CRP-XL (0.5 lg mL1). Fluorescence
measurements with excitation at 340 and 380 nm and
emission at 510 nm were recorded using a NOVOstar
plate reader (BMG Labtech, Aylesbury, UK) [23,24].
Platelet integrin activation, adhesion and clot retraction
assays
Washed platelets (2 9 108 cells mL1) were diluted in HBS
containing either anti-human-fibrinogen or PAC-1 anti-
body (1 : 500 dilution) and either anti-ERp72 or control
antibody added for 5 min. Platelets were stimulated with
CRP-XL (0.5 lg mL1) for 20 min and then fixed by dilu-
tion in paraformaldehyde (0.2% v/v). Data for 10 000
gated events were recorded using an Accuri C6 flow
cytometer (Beckton Dickinson). Platelet adhesion onto col-
lagen or fibrinogen-coated surfaces in the presence of either
anti-ERp72 or control antibody was measured by static
adhesion assay as described previously [25]. Clot retraction
was measured as described previously [14].
Assessment of arterial thrombus formation in vivo
Male C57BL/6J mice were anesthetized by intraperitoneal
injection of ketamine (125 mg kg1), xylazine
(12.5 mg kg1) and atropine (0.25 mg kg1). Platelets
were labelled by infusion of DyLight 649-conjugated anti-
GPIb antibody (0.2 lg g1 bodyweight). Following expo-
sure of the testicular cremaster muscle, anti-ERp72 or
control antibody (12.5 ug g1 bodyweight) was infused
and following a 5-min incubation period, arteriole wall
injury was induced by ablation laser (Micropoint, Andor
Technology, Belfast, UK). Thrombi were observed using
an Olympus BX microscope (Olympus, Southend-on Sea,
UK) and a Hamamatsu (Hamamatsu Photonics, Welwyn
Garden City, UK) CCD camera and data analyzed using
Slidebook Software version 5.0 (Intelligent Imaging Inno-
vations, Denver, CO, USA) [26]. Animal experiments
were approved by the University of Reading Local Ethi-
cal Review Panel and authorized by the UK Home
Office.
Data analysis
Data were analyzed using GraphPad Prism software and
statistical analysis performed using one-way ANOVA
(ERp72 activity assay, platelet aggregation assays, dense
granule secretion and mouse platelet flow cytometry
assays). Student’s t-test was used to analyze all other
datasets with intravital time to peak fluorescence data
additionally being analyzed using the Mann–Whitney U-
test. Non-normalized data were used for statistical analy-
sis. Data where P < 0.05 were considered to reach statisti-
cal significance.
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Results
Anti-ERp72 inhibits ERp72 enzyme activity
Eleven Anti-ERp72 antibodies were screened for their
abilities to inhibit the thiol isomerase activity of ERp72
(data not shown) and platelet aggregation, and the most
potent in both assays, clone AbD17115 (herein termed
anti-ERp72), was used for all experiments.
The selectivity of anti-ERp72 was verified by immu-
noblot analysis of recombinant ERp72, ERp57, PDI
and ERp5, TMX3, ERp46 and TRX (Fig. 1A). No
reactivity with ERp57, PDI, ERp5, TMX3, ERp46 or
TRX was observed. A small number of feint high-mole-
cular-weight bands above the expected weight of
72KDa in the whole platelet lysate lane were observed,
which may correspond to ERp72-substrate complexes.
Figure 1(B) illustrates the proteins analyzed. To verify
that anti-ERp72 is able to selectively inhibit ERp72
thiol isomerase activity, the self-quenching fluorescent
substrate DI-E-GSSG was used. We observed that
ERp72 (100 nM) has redox activity as identified by an
increase in fluorescence over time (Fig. 1C). Pre-incuba-
tion of ERp72 protein with anti-ERp72 (25 lg mL1)
decreased the reduction of Di-E-GSSG substrate by
40% (control MFI 8278  602, anti-72 MFI
4980  414) compared with control antibody treatment
in a 30-min endpoint assay (Fig. 1D). Anti-ERp72 had
no significant effect on the activity of all other thiol
isomerases tested, thus verifying its selectivity (Fig.
1E–J).
Anti-ERp72 diminishes platelet aggregation and fibrinogen
binding to integrin aIIbb3
To explore whether cell-surface ERp72 regulates platelet
responses, aggregation assays were performed in the
presence of control antibody or anti-ERp72. Platelets
were stimulated for 180 s with collagen (1 lg mL1,
Fig. 2A, B) or thrombin (0.1 U mL1, Fig. 2C, D) fol-
lowing pre-incubation (5 min) with either anti-ERp72
(10–25 lg mL1) or control antibody (25 lg mL1). Pla-
telet aggregation in response to both collagen and
thrombin stimulation was inhibited in a concentration-
dependent manner in the presence of anti-ERp72. At
the highest concentration tested (25 lg mL1) anti-
ERp72 inhibited collagen-stimulated aggregation by
49%  7.1%; thrombin-induced aggregation was inhib-
ited more substantially, with an inhibition of 79%
( 5.7%) compared with control antibody-treated plate-
lets. No inhibition of aggregation was observed in the
presence of control antibody.
Fibrinogen ligation following platelet activation was
measured using flow cytometry-based analysis of fibrino-
gen binding to the platelet surface. Human platelets were
stimulated using the GPVI selective peptide agonist CRP-
XL (0.5 lg mL1). Fibrinogen binding levels post-activa-
tion for control antibody-treated platelets were 22203
( 633.4 AU); anti-ERp72 treatment resulted in a 76%
(5243  3769 AU) decrease in fibrinogen binding com-
pared with the control (Fig. 2E).
ERp72 modulates platelet granule secretion and calcium
mobilization
Since anti-ERp72 treatment resulted in an inhibition of
platelet aggregation and associated fibrinogen ligation, we
hypothesized that ERp72 may play a role in regulating
events leading to the secretion of fibrinogen from
platelet alpha-granules. To test this, the effects of anti-
ERp72 on alpha-granule secretion were measured by
analysis of P-selectin exposure. Pre-treatment of human
platelets with control antibody had no effect on their abil-
ity to secrete P-selectin (MFI 6096  1612). Anti-ERp72
decreased P-selectin exposition from alpha-granules by
88% (MFI 735.2  128.3) (Fig. 3A). Mouse platelets
were stimulated using thrombin (0.1U mL1) in the pres-
ence of anti-ERp72 at concentrations of either 25 or
50 lg mL1 (Fig. 3B). Compared with control antibody-
treated platelets (50 lg mL1, MFI 2469  58.26), the
highest concentration of anti-ERp72 resulted in a 30%
inhibition of P-selectin exposure (MFI 1737  456.9).
The effects of ERp72 inhibition on platelet dense-gran-
ule secretion were measured using lumi-aggregometry.
Human platelets, pre-incubated with varying concentra-
tions of anti-ERp72 (10–25 lg mL1) or control antibody
(25 lg mL1) were stimulated with collagen (1 lg mL1)
in the presence of Chronolume substrate. Pre-incubation
with control antibody had no effect on the ability of plate-
lets to secrete ATP. Compared with levels of ATP secretion
in control antibody treated-samples, concentration-depen-
dent inhibition of dense-granule secretion was observed in
the presence of anti-ERp72 (Fig. 3C), with the highest con-
centration of anti-ERp72 (25 lg mL1) decreasing ATP
secretion by 54.7%  9.8%. Similarly, previous studies
have demonstrated that specific inhibition of ERp5, PDI
[10] and ERp57 [14] and broad-spectrum thiol isomerase
inhibition using the antibiotic bacitracin [27] results in the
impairment of human platelet granule secretion.
We were interested to determine if early signaling
events downstream of GPVI were influenced by ERp72
and therefore cytosolic calcium mobilization from intra-
cellular stores was measured by fluorimetric assay follow-
ing stimulation with the GPVI selective agonist CRP-XL.
In the presence of control antibody, GPVI stimulation
resulted in an increase in cytosolic calcium followed by
the anticipated decrease in Ca2+ levels. Inhibition of
ERp72 diminished the post-activation calcium flux sub-
stantially (Fig. 4A). In comparison with human platelets
treated with control antibody, ERp72 inhibition resulted
in a 56% (13.3%) decrease in peak cytosolic Ca2+
levels (Fig. 4B).
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Fig. 1. Anti-ERp72 selectively inhibits ERp72 enzyme activity. Human whole platelet lysate (8 9 108 cells mL1) and recombinant ERp72,
ERp57, PDI, ERp5, TMX3, ERp46 and TRX (all 5 lg) were separated by reducing SDS PAGE and immunoblotted with (A) anti-ERp72
(1 lg mL1 diluted in 2% w/v BSA/TBS-T) and FITC-conjugated anti-human secondary antibody (1 : 1000 dilution in 2% w/v BSA/TBS-T)
or (B) stained with Coomassie blue protein stain to reveal total protein loading. (C) Thiol isomerase activity of ERp72 was measured by fluo-
rescence-based thiol isomerase assay. Anti-ERp72 (open circles) or control antibody (closed squares, both 25 lg mL1) were incubated with
recombinant ERp72 (100 nM) for 5 min, prior to the addition of DTT (0.5 lM) and DI-E-GSSG substrate. Fluorescence values were recorded
at 5-min intervals for a total of 30 min. (D) Inhibition of ERp72 enzyme activity, (E) ERp57 activity, (F) PDI activity, (G) ERp5 activity, (H)
TMX3 activity, (I) ERp46 activity or (I) TRX activity at 30 min in the presence of control antibody (open histogram) or anti-ERp72 (closed
histogram) (n = 5). Graphs represent mean  SEM. P values were calculated by one-way ANOVA (C) or Student’s t-test (D–J), (*P < 0.01,
**P < 0.01).
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ERp72 regulates integrin aIIbb3 activation and signaling
Because fibrinogen binding, granule secretion and calcium
mobilization were impaired by ERp72 inhibition, it was
relevant to determine if this was likely to impact on the
ability of integrin aIIbb3 to undergo affinity modulation
and thus effect inside-out and outside-in signaling
through this receptor. Recent studies have provided evi-
dence to support the notion that integrins can convert
from a low-affinity state to a high-affinity ligand binding
state in a fashion that is associated with disulfide bond
rearrangement leading to the exposure of free thiols. Pre-
vious studies have implicated PDI in orchestrating this
process [13,28,29]. Integrin affinity modulation was
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antibody (25 lg mL1) or anti-ERp72 (10–25 lg mL1) for 5 min prior to stimulation with (A) collagen (1 lg mL1) or (C) thrombin
(0.1U mL1) for 180 s. (B) Percentage platelet aggregation for control antibody-treated samples (25 lg mL1, open histogram) and anti-
ERp72-treated platelets (10 lg mL1, light grey histogram; 15 lg mL1, dark grey histogram; 25 lg mL1, closed histogram); n = 3 for colla-
gen stimulation or (D) n = 4 for thrombin stimulation. Fibrinogen binding, compared with control antibody binding levels (E, n = 3) was mea-
sured by flow cytometry. Platelets (2 9 108 cells mL1) were incubated with control antibody (25 lg mL1, open histogram) or anti-ERp72
(25 lg mL1, closed histogram) for 5 min prior to stimulation with CRP-XL (0.5 lg mL1) and fibrinogen binding was analyzed by flow
cytometry. Data for 10 000 gated events were recorded. Graphs represent mean  SEM. P values were calculated by Student’s t-test (E) or
one-way ANOVA (A––D), (*P < 0.05,**P < 0.01, ***P < 0.005).
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assessed using the monoclonal antibody PAC-1 that rec-
ognizes an epitope exposed following activation-depen-
dent conformational change in integrin aIIbb3. In both
control antibody-treated and anti-ERp72-treated human
platelets, two populations of cells were observed following
activation, suggesting that some platelets in the popula-
tion express either an unactivated or less activated form
of integrin aIIbb3. The majority of cells exhibited lower
fluorescence on their cell surface, suggesting less antibody
binding, consistent with lower levels of activation. When
compared with the control antibody-treated cells (MFI
21374  637.5), anti-ERp72 treatment resulted in a 77%
(MFI 4984  2834) decrease in integrin activation
(Fig. 5A). In mouse platelets, integrin aIIbb3 activation
was measured using the mouse-specific JON/A antibody.
In response to thrombin stimulation (0.1 U mL1), con-
trol antibody (50 lg mL1) treated platelets exhibited an
MFI of 489.9 ( 25.51) whereas anti-ERp72 treatment
diminished JON/A binding by 41% (MFI 290.3  42.3,
Fig. 5B). To determine if the observed decrease in
fibrinogen binding and integrin activation impacts on the
capacity of the platelet to adhere to fibrinogen, static
adhesion of human platelets onto a fibrinogen-coated sur-
face was analyzed. Inhibition of ERp72 activity decreased
the ability of platelets to adhere to fibrinogen-coated sur-
faces by 34% (3.3%, Fig. 5C) compared with control
antibody treatment.
Our data revealed the ability of ERp72 function-block-
ing antibodies to inhibit fibrinogen binding to the platelet
surface by inhibition of inside-out signaling. This would
be expected to impact on the initiation and strength of
outside-in signaling to the actin cytoskeleton, which is
responsible for clot retraction and compaction of growing
thrombi in vivo. The ability of ERp72 blockade to influ-
ence outside-in signaling was measured by clot retraction
assay. In comparison to control antibody-treated blood,
clot weight was increased by 77.3% ( 11.13%) in the
presence of anti-ERp72 (Fig. 5D). These data suggest
that ERp72 regulates integrin affinity modulation, which
serves to increase fibrinogen binding to the receptor and
leads to outside-in signaling through integrin aIIbb3.
Inhibitory anti-ERp72 modulates thrombus formation in vivo
The effects of the inhibitory anti-ERp72 on arterial
thrombus formation were determined by intravital micro-
scopy. Murine platelets were labeled by infusion of anti-
GPIb DyLight 649 antibody and thrombus formation
measured following cremaster muscle arteriole injury in
the presence of either anti-ERp72 or control antibody.
Figure 6(A) shows time-resolved representative images of
thrombi formed in the presence of control antibody.
Thrombi formed in the presence of anti-ERp72 are illus-
trated in Fig. 6(B). Median thrombus fluorescence for
control antibody (n = 24 thrombi) and anti-ERp72
(n = 36 thrombi) treated mice (Fig. 6C) revealed that
although similar peak fluorescence values were obtained
for both treatment conditions, the time to reach peak flu-
orescence and therefore thrombus formation time was sig-
nificantly delayed in the presence of anti-ERp72
(Fig. 6D). Following laser injury, peak thrombus forma-
tion in the presence of control antibody was observed
after 96 s ( 16.55 s), whereas pre-treatment of mice with
anti-ERp72 resulted in delayed maximal thrombus forma-
tion (168.9  13.59 s). These findings are consistent with
the effects of anti-ERp72 on platelet function and confirm
an important role for ERp72 in the regulation of throm-
bus formation.
Discussion
In recent years, PDI family members released from plate-
lets and endothelial cells have been shown to be impor-
tant mediators of platelet function, thrombosis and
hemostasis [10,14–18,30]. In 2009 we identified ERp72 to
be present in human and mouse platelets, and that resting
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platelets expose low levels of ERp72 on the platelet sur-
face, which increases substantially upon stimulation [11],
although the exact mechanism by which ERp72 and other
thiol isomerases associate with the platelet surface is still
poorly understood. In other cell types, ERp72 is known
to play diverse roles both in the ER and at the cell sur-
face; however, in platelets, the function of ERp72 has
only recently been explored [31].
Humanized FC-null antibodies that selectively block
the enzymatic activity of recombinant ERp72 were gener-
ated and their selectivity verified. Of the antibodies gener-
ated, anti-ERp72 was found to exert an inhibitory effect
on a wide range of platelet functional responses, including
aggregation, secretion, calcium mobilization and integrin
activation in both human and mouse platelets. Interest-
ingly, greater concentrations of anti-ERp72 were required
to inhibit mouse platelet responses than observed for
human platelets. A possible explanation for this difference
is that mouse platelets contain substantially more copies
of ERp72 (21 607) than their human counterparts (8500
copies), and therefore more antibody is required to effec-
tively block ERp72 activity [32,33]. The application of
anti-ERp72 confirmed previous findings that some assays
of platelet function are sensitive to differential regulation
by thiol isomerases, for example ERp72 and ERp57
blockade inhibits GPVI-stimulated Ca2+ flux [14] but
ERp5 and PDI ablation does not [10,30]. P-selectin expo-
sure is affected by ERp72 and ERp5 inhibition [10] but
not by ERp57 inhibition or PDI deficiency [14,30]. Simi-
larly, ERp72 inhibition has a more limited impact on pla-
telet adhesion to fibrinogen than other thiol isomerases
despite its ability to impair both integrin activation and
fibrinogen ligation. Collectively, these data suggest that
individual thiol isomerases may exert common and differ-
ential effects on platelet activation pathways or act at dif-
ferent sites with different substrates.
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Fig. 5. ERp72 plays a role in the regulation of integrin-mediated adhesion, activation and signalling. Integrin activation in the presence of
anti-ERp72 was measured by flow cytometry-based analysis of PAC-1 antibody binding in human platelets (A) or JON/A binding in mouse
platelets (B). Platelets (2 9 108 cells mL1) were incubated with control antibody (25 lg, open histogram) or anti-ERp72 (25 lg, closed his-
togram) for 5 min prior to stimulation with 0.5 lg mL1 CRP-XL, n = 3, and detection by flow cytometry. Mouse platelet integrin activation
in the presence of 25 or 50 lg mL1 anti-ERp72 or control antibody was stimulated using thrombin (0.1 U mL1); n = 4. Integrin-mediated
adhesion was measured by static adhesion ELISA. (C) Platelets (1 9 108 cells mL1), pre-treated with either control antibody (25 lg, open his-
togram) or anti-ERp72 (25 lg, closed histogram), were adhered to fibrinogen (100 lg mL1) coated wells, adherent cells were lysed and per-
centage of adhesion quantified by acid phosphatase assay; n = 3. Outside-in signalling was measured by clot retraction assay. Human platelet-
rich plasma (PRP) (diluted using PPP to 4 9 108 cells mL1) was incubated with either control antibody (25 lg) or anti-ERp72 (25 lg) for
5 min and following the addition of thrombin (1U mL1) clot retraction was measured after 1 h. (D) Percentage clot weight with control anti-
body (open histogram) or anti-ERp72 antibody (closed histogram); n = 4. Graphs represent mean  SEM. P values were calculated by Stu-
dent’s t-test (A, C and D) or one-way ANOVA (B) (*P < 0.05, **P < 0.01).
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Infusion of anti-ERp72 into mice resulted in delayed
thrombus formation, suggesting that ERp72, like ERp5,
PDI and ERp57, is crucial for normal platelet function.
In contrast to other studies where PDI or ERp57 inhibi-
tion leads to almost complete abolition of thrombus for-
mation, treatment with anti-ERp72 did not prevent
thrombus formation, but it was significantly delayed.
These data suggest that ERp72 may be important for
early platelet accumulation at the site of injury, impacting
on the thrombus stability, and less so in the later stages
of thrombus formation.
While this manuscript was under review, a study using a
conditional ERp72 knockout mouse was published that
corroborates our findings that ERp72 is important for pla-
telet activation and granule secretion and revealed that sim-
ilar to ERp57 and PDI, ERp72 is able to form a functional
association with, and modulate changes in, the thiol con-
tent of integrin aIIbb3. However, despite this common
mode of substrate interaction, platelet aggregation in the
absence of ERp72, ERp57 or PDI was only rescued
through supplementation with the respective enzyme that
was absent. This apparent lack of redundancy between dif-
ferent platelet thiol isomerases suggests that each enzyme
possesses an individual role [31], although the precise sub-
strates of each enzyme remain unclear.
In other cell types ERp72 is known to act as a regulator
of interferon-c, thyroglobulin and cholera toxin folding
within the ER, and at the cell surface it is known to inter-
act with, and be regulated by, the reactive oxygen species
(ROS) generating enzyme NADPH oxidase (NOX-1).
Becauses NOX-1 is known to be essential for GPVI-stimu-
lated and ROS-mediated thromboxane A2 generation in
platelets [34] it will be important to determine if platelet
surface ERp72 activity is regulated by NOX-1 and how
this impacts on platelet function. Additionally, a recent
report provided evidence that binding of substrates to
ERp72 can promote an allosteric conformational switch in
ERp72 protein that augments catalytic activity. This fea-
ture is shared with PDI but not ERp5 or ERp57 [35].
These reports highlight the potential biochemical
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Fig. 6. Anti-ERp72 modulates thrombus formation in vivo. The effects of anti-ERp72 on thrombus formation in mice were determined follow-
ing laser injury of cremaster muscle arterioles and observed by intravital microscopy. Male C57/BL6 circulating mouse platelets were labelled
with DyLight 649-conjugated anti-GPIb antibody (0.2 lg g1 bodyweight) and either control antibody (A) or anti-ERp72 (12.5 lg g1 body-
weight) (B) infused. Following laser injury, images were recorded for 5 min. (C) Time-series data for median fluorescence intensity of thrombi
formed in control antibody-treated mice (n = 24 thrombi, black line graph) or anti-ERp72-treated mice (n = 36 thrombi, red line graph). The
position of the cremaster vessel is denoted by white lines and the direction of blood flow indicated by a red arrow on the pre-injury images.
(D) Analysis of time to peak fluorescence values for control antibody (open histogram) and anti-ERp72 treatment (closed histogram).
**P < 0.01, data analyzed using Student’s t-test and the Mann–Whitney U-test.
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differences in substrate binding activities between different
thiol isomerases but the importance of this in the context
of platelet function regulation is not yet clear.
Based on the data presented in this study, we demon-
strate that ERp72 plays an important role in regulating
platelet signaling and receptor activation events underpin-
ning platelet activation and thrombus formation. ERp72
becomes enriched at the platelet surface early on in plate-
let activation and we propose that through substrate
interaction there, disulfide bond modification or interac-
tions with other thiol isomerases, ERp72 is able to influ-
ence the transition of the activation state of integrin
aIIbb3 from a low-affinity state to a high-affinity, fibrino-
gen binding conformer. This switch in integrin activity
results in the enhancement of platelet adhesion, outside-in
signaling and therefore enhanced thrombus formation.
Further investigation is required to determine the exact
mode of action of platelet-surface ERp72.
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